Milrinone: basic and clinical pharmacology and acute and chronic management
| Autor: | Joshua B. Shipley, David Tolman, Andrea Hastillo, Michael L. Hess |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Heart Failure
Male Clinical Trials as Topic Pulmonary Circulation Cardiotonic Agents Phosphodiesterase Inhibitors Pyridones Contraindications Vasodilator Agents Administration Oral General Medicine Middle Aged Myocardial Contraction Acute Disease Injections Intravenous Cyclic AMP Humans Drug Therapy Combination Female Vascular Resistance Calcium Channels Cardiac Output Milrinone |
| Zdroj: | The American journal of the medical sciences. 311(6) |
| ISSN: | 0002-9629 |
| Popis: | Milrinone (Inocor-Sanofi-Winthrop) represents a second generation phosphodiesterase inhibitor currently approved for intravenous administration in the treatment of decompensated congestive heart failure. By inhibiting Type III phosphodiesterase, milrinone increases intracellular cyclic adenosine monophosphate. This results in a positive inotropic effect on the heart and vasodilatation in the periphery. The hemodynamic consequences of this action produce left ventricular afterload reduction, with an increase in cardiac output and a reduction in total peripheral resistance. Unlike the sympathomimetic amines, milrinone produces no tolerance and possesses the distinct advantage of directly decreasing pulmonary vascular resistance. Short-term intermittent infusion by peripheral administration, continuous infusion, long-term therapy, and intermittent outpatient therapy was demonstrated to be safe, efficacious, and cost effective. It is hypothesized that intravenous milrinone, by producing biventricular afterload reduction, offers an efficacious, cost-effective tool for the treatment of decompensated heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|